Jacobs Levy Equity Management
VIVO

Jacobs Levy Equity Management’s Meridian Bioscience Inc VIVO Stock Holding History

Jacobs Levy Equity Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,019
Closed -$222K – 1160
2021
Q2 		$222K Buy
+10,019
New +$213K ﹤0.01% 971
2020
Q2 		– Sell
-36,461
Closed -$306K – 1181
2020
Q1 		$306K Sell
36,461
-199,065
-85% -$1.68M ﹤0.01% 824
2019
Q4 		$2.3M Buy
+235,526
New +$2.21M 0.02% 519

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Jacobs Levy Equity Management's VIVO Position: Q3 2021 in Review

Jacobs Levy Equity Management sold out of Meridian Bioscience Inc (VIVO) in Q3 2021, closing a stake of 10,019 shares — an estimated $222K sold.

Jacobs Levy Equity Management first reported a position in VIVO in Q4 2019 and held it in 3 quarters. The position peaked at $2.3M in Q4 2019. 180 funds tracked by Wall St. Rank hold VIVO as of Q3 2021.

  • Jacobs Levy Equity Management reported no remaining Meridian Bioscience Inc position as of Q3 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 10,019 Meridian Bioscience Inc shares in Q3 2021, an estimated $222K.
  • Jacobs Levy Equity Management first reported a position in Meridian Bioscience Inc in Q4 2019 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Meridian Bioscience Inc position peaked at $2.3M in Q4 2019.
  • 180 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2021, filed 15 Nov 2021.